Literature DB >> 17715137

Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.

Ira B Dicker1, Himadri K Samanta, Zhufang Li, Yang Hong, Yuan Tian, Jacques Banville, Roger R Remillard, Michael A Walker, David R Langley, Mark Krystal.   

Abstract

Human immunodeficiency virus (HIV) integrase enzyme is required for the integration of viral DNA into the host cell chromosome. Integrase complex assembly and subsequent strand transfer catalysis are mediated by specific interactions between integrase and bases at the end of the viral long terminal repeat (LTR). The strand transfer reaction can be blocked by the action of small molecule inhibitors, thought to bind in the vicinity of the viral LTR termini. This study examines the contributions of the terminal four bases of the nonprocessed strand (G(2)T(1)C(-1)A(-2)) of the HIV LTR on complex assembly, specific strand transfer activity, and inhibitor binding. Base substitutions and abasic replacements at the LTR terminus provided a means to probe the importance of each nucleotide on the different functions. An approach is described wherein the specific strand transfer activity for each integrase/LTR variant is derived by normalizing strand transfer activity to the concentration of active sites. The key findings of this study are as follows. 1) The G(2):C(2) base pair is necessary for efficient assembly of the complex and for maintenance of an active site architecture, which has high affinity for strand transfer inhibitors. 2) Inhibitor-resistant enzymes exhibit greatly increased sensitivity to LTR changes. 3) The strand transfer and inhibitor binding defects of a Q148R mutant are due to a decreased affinity of the complex for magnesium. 4) Gln(148) interacts with G(2), T(1), and C(-1) at the 5' end of the viral LTR, with these four determinants playing important and overlapping roles in assembly, strand transfer catalysis and high affinity inhibitor binding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17715137     DOI: 10.1074/jbc.M704935200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs.

Authors:  Akram Alian; Sarah L Griner; Vicki Chiang; Manuel Tsiang; Gregg Jones; Gabriel Birkus; Romas Geleziunas; Andrew D Leavitt; Robert M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-04       Impact factor: 11.205

2.  Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

Authors:  Ira B Dicker; Brian Terry; Zeyu Lin; Zhufang Li; Sagarika Bollini; Himadri K Samanta; Volodymyr Gali; Michael A Walker; Mark R Krystal
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

Review 3.  Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors:  Alan N Engelman
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

4.  Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.

Authors:  Barry C Johnson; Mathieu Métifiot; Yves Pommier; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

5.  Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

Authors:  Kendra E Hightower; Ruolan Wang; Felix Deanda; Brian A Johns; Kurt Weaver; Yingnian Shen; Ginger H Tomberlin; H Luke Carter; Timothy Broderick; Scott Sigethy; Takahiro Seki; Masanori Kobayashi; Mark R Underwood
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

7.  Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

Authors:  Mark G Lewis; Sandro Norelli; Matt Collins; Maria Letizia Barreca; Nunzio Iraci; Barbara Chirullo; Jake Yalley-Ogunro; Jack Greenhouse; Fausto Titti; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2010-03-16       Impact factor: 4.602

8.  A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain.

Authors:  Kevin Carayon; Hervé Leh; Etienne Henry; Françoise Simon; Jean-François Mouscadet; Eric Deprez
Journal:  Nucleic Acids Res       Date:  2010-02-17       Impact factor: 16.971

Review 9.  Recent Advances in the Development of Integrase Inhibitors for HIV Treatment.

Authors:  Jay Trivedi; Dinesh Mahajan; Russell J Jaffe; Arpan Acharya; Debashis Mitra; Siddappa N Byrareddy
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

10.  Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Authors:  Olivia Goethals; Reginald Clayton; Marcia Van Ginderen; Inge Vereycken; Elisabeth Wagemans; Peggy Geluykens; Koen Dockx; Rudy Strijbos; Veerle Smits; Ann Vos; Geert Meersseman; Dirk Jochmans; Kurt Vermeire; Dominique Schols; Sabine Hallenberger; Kurt Hertogs
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.